Young Soo Rho1, Marine Gilabert2, Karol Polom3, Archil Aladashvili4, Katerina Kopeckova5, Vera Megdanova6, Niamh Coleman7, Megan Greally7, Daniele Marrelli3, Franco Roviello3, Ray McDermott6, Veneta Petrova6, Zhasmina Mihaylova6, Zbynek Bortlicek8, Jana Prausova5, Gerald Batist9, Laurent Azoulay10, Petr Kavan11. 1. Gerald Bronfman Department of Oncology, McGill University Faculty of Medicine, Montreal, QC, Canada. 2. Department of Medical Oncology, Paoli-Calmettes Institute, Marseille, France. 3. General and Oncological Surgery Department, University of Siena, Siena, Italy. 4. GI Cancer Research Unit and Oncology Surgery, National Cancer Center, Tbilisi, Georgia. 5. Department of Oncology, Second Faculty of Medicine-Charles University Prague and Motol University Hospital, Prague, Czech Republic. 6. Department of Medical Oncology, Military Medical Academy, Sofia, Bulgaria. 7. Department of Medical Oncology, St. Vincent's University Hospital, Dublin, Ireland. 8. Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic. 9. Gerald Bronfman Department of Oncology, McGill University Faculty of Medicine, Montreal, QC, Canada; Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital-McGill University, Montreal, QC, Canada. 10. Gerald Bronfman Department of Oncology, McGill University Faculty of Medicine, Montreal, QC, Canada; Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital-McGill University, Montreal, QC, Canada; Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada. 11. Gerald Bronfman Department of Oncology, McGill University Faculty of Medicine, Montreal, QC, Canada; Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital-McGill University, Montreal, QC, Canada. Electronic address: petr.kavan@mcgill.ca.
Abstract
BACKGROUND: Compared with the general population, the incidence of young-onset (YO) colorectal cancer (CRC) is increasing. However, a significant knowledge gap exists in the clinical characteristics, treatment patterns, and outcomes for these patients. MATERIALS AND METHODS: Six international tertiary cancer centers conducted a retrospective study. Patients with YO CRC (aged 18-44 years) and LO CRC (aged > 44 years) diagnosed with histologically proven colorectal adenocarcinoma from June 2003 to June 2014 were enrolled. Patients were randomly chosen from each center's database, and the patient demographics and treatment information were collected. The data were then centralized, and the final analysis was performed at a single institution. Cox proportional hazards models were used to estimate the crude and adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) for progression-free survival and mortality, and YO was compared with LO. Site-specific HRs were pooled using a random-effects meta-analysis. RESULTS: Overall, 498 patients, including 224 with YO (129 men; mean age, 37 ± 5.5 years) and 274 with LO (167 men; mean age, 64.8 ± 9.5 years) CRC, were included. At the diagnosis, 137 patients (61.2%) and 122 patients (44.5%) with YO and LO CRC had metastatic disease, respectively. For both cohorts, the 3 most common presenting symptoms were pain, hematochezia, and weight loss. Surgery was performed in 141 YO (63.0%) and 219 LO (79.9%) patients. The longitudinal noncurative treatment patterns were similar, but more biologic therapy was used for these YO patients. The pooled progression-free survival analysis results for first-line noncurative treatment favored LO (HR, 1.96; 95% CI, 1.04-3.68). The mortality analysis showed no significant differences between the 2 groups (YO: HR, 1.53; 95% CI, 0.91-2.58). CONCLUSION: Despite similar treatment patterns and survival outcomes, YO disease might be clinically more aggressive.
BACKGROUND: Compared with the general population, the incidence of young-onset (YO) colorectal cancer (CRC) is increasing. However, a significant knowledge gap exists in the clinical characteristics, treatment patterns, and outcomes for these patients. MATERIALS AND METHODS: Six international tertiary cancer centers conducted a retrospective study. Patients with YO CRC (aged 18-44 years) and LO CRC (aged > 44 years) diagnosed with histologically proven colorectal adenocarcinoma from June 2003 to June 2014 were enrolled. Patients were randomly chosen from each center's database, and the patient demographics and treatment information were collected. The data were then centralized, and the final analysis was performed at a single institution. Cox proportional hazards models were used to estimate the crude and adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) for progression-free survival and mortality, and YO was compared with LO. Site-specific HRs were pooled using a random-effects meta-analysis. RESULTS: Overall, 498 patients, including 224 with YO (129 men; mean age, 37 ± 5.5 years) and 274 with LO (167 men; mean age, 64.8 ± 9.5 years) CRC, were included. At the diagnosis, 137 patients (61.2%) and 122 patients (44.5%) with YO and LO CRC had metastatic disease, respectively. For both cohorts, the 3 most common presenting symptoms were pain, hematochezia, and weight loss. Surgery was performed in 141 YO (63.0%) and 219 LO (79.9%) patients. The longitudinal noncurative treatment patterns were similar, but more biologic therapy was used for these YO patients. The pooled progression-free survival analysis results for first-line noncurative treatment favored LO (HR, 1.96; 95% CI, 1.04-3.68). The mortality analysis showed no significant differences between the 2 groups (YO: HR, 1.53; 95% CI, 0.91-2.58). CONCLUSION: Despite similar treatment patterns and survival outcomes, YO disease might be clinically more aggressive.
Authors: Xu-Feng Zhang; Eliza W Beal; Jeffery Chakedis; Qinyu Chen; Yi Lv; Cecilia G Ethun; Ahmed Salem; Sharon M Weber; Thuy Tran; George Poultsides; Andre Y Son; Ioannis Hatzaras; Linda Jin; Ryan C Fields; Stefan Buettner; Charles Scoggins; Robert C G Martin; Chelsea A Isom; Kamron Idrees; Harveshp D Mogal; Perry Shen; Shishir K Maithel; Carl R Schmidt; Timothy M Pawlik Journal: World J Surg Date: 2018-09 Impact factor: 3.352
Authors: Jeremy R Burt; Jeffrey Waltz; Ashley Ramirez; Andres Abadia; Basel Yacoub; Sydney A Burt; Fiona Tissavirasingham; Madison R Kocher Journal: Abdom Radiol (NY) Date: 2020-09-16